Cargando…
Gemcitabine plus S-1 for metastatic pancreatic cancer
To investigate the treatment effects of gemcitabine plus S-1 (GS) for metastatic pancreatic cancer in our institution. Data from 41 patients with metastatic pancreatic cancer treated with GS regimen in West China Hospital, Sichuan University were reviewed. The therapeutic efficacy and toxicity were...
Autores principales: | Zhu, Hong, Yi, Cheng, Zhao, Yaqin, Gou, Hongfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203537/ https://www.ncbi.nlm.nih.gov/pubmed/30313120 http://dx.doi.org/10.1097/MD.0000000000012836 |
Ejemplares similares
-
Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018) -
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018) -
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016) -
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)